Skip to main content
OpenTrials
Completed

NCT Number: NCT01055119

Effect of Long Chain Polyunsaturated Fatty Acids on Behavior and Cognition in Children With Attention Deficit Hyperactivity Disorder

The study investigates whether eicosapentaenoic/docosahexaenoic acid supplementation affects behavior and cognition in children with attention deficit hyperactivity disorder.

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 year–12 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Klinik fuer Psychiatrie und Psychotherapie III, Ulm, Baden-Wurttemberg, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ADHD diagnosis
  • Age 9-12y
  • Native German speaker

Exclusion criteria

  • Allergy against fish and fish products
  • IQ below 85
  • Objections against pork gelatine

Treatment and study plan

Omega-3 fatty acids

Dietary Supplement

duration: 4 month

Primary outcomes

  1. Behavior, Cognition

    Time frame: Before intervention and 16 weeks after start of intervention

Sponsors and collaborators

Lead sponsor

University of Ulm

Other

Registry information

Official study title

Effect of Supplementation With Long Chain Polyunsaturated Fatty Acids on Behavior and Cognition in Children With Attention Deficit Hyperactivity Disorder

Acronym: EFA

Important dates

Study start
2009
Primary completion
2012
Study completion
2012
First posted
Jan 25, 2010
Registry last updated
May 3, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.